The estimated Net Worth of Robert Jr. Leasure is at least $82.2 Tisíc dollars as of 24 February 2021. Mr. Leasure owns over 5,000 units of Basis Global Technologies Inc stock worth over $82,200 and over the last 6 years he sold BASI stock worth over $0. In addition, he makes $0 as President, Chief Executive Officer a Director at Basis Global Technologies Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Leasure BASI stock SEC Form 4 insiders trading
Robert has made over 11 trades of the Basis Global Technologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of BASI stock worth $72,100 on 24 February 2021.
The largest trade he's ever made was buying 26,846 units of Basis Global Technologies Inc stock on 13 September 2019 worth over $99,867. On average, Robert trades about 7,702 units every 52 days since 2019. As of 24 February 2021 he still owns at least 5,000 units of Basis Global Technologies Inc stock.
You can see the complete history of Mr. Leasure stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Leasure biography
Robert Leasure is President, Chief Executive Officer, Director of the company. Since September of 2016, Mr. Leasure has worked closely with the Company's management team and board of directors to guide operations and assist BASi in restructuring and developing a growth strategy for the Company. Mr. Leasure's experience leading the Company's turnaround, including the Company's refinancing, its acquisition of Seventh Wave Laboratories, Inc., and its execution of expansion and growth plans over the last two years, ideally positions him for the role of President and Chief Executive Officer and as a director. BASi's board believes Mr. Leasure's demonstrated successes, experience, ability to develop and work collaboratively with the management team, and his ability to create and execute upon visions for the future of the Company have been, and will continue to be, critical to growing the Company's business and creating long-term shareholder value.
What's Robert Leasure's mailing address?
Robert's mailing address filed with the SEC is C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE, IN, 47906-1382.
Insiders trading at Basis Global Technologies Inc
Over the last 21 years, insiders at Basis Global Technologies Inc have traded over $266,443 worth of Basis Global Technologies Inc stock and bought 540,162 units worth $1,698,287 . The most active insiders traders include Jacqueline M Lemke, Robert Jr. Leasure a William D Pitchford. On average, Basis Global Technologies Inc executives and independent directors trade stock every 65 days with the average trade being worth of $128,544. The most recent stock trade was executed by Beth Taylor on 5 March 2021, trading 5,000 units of BASI stock currently worth $88,500.
What does Basis Global Technologies Inc's logo look like?
Complete history of Mr. Leasure stock trades at Basis Global Technologies Inc
Basis Global Technologies Inc executives and stock owners
Basis Global Technologies Inc executives and other stock owners filed with the SEC include:
-
Wendy Perrow,
Independent Director -
R. Matthew Neff,
Independent Director -
Richard Johnson,
Independent Director -
Joseph Flynn,
Chief Commercial Officer -
John Sagartz,
Chief Strategy Officer, Director -
Connie Dougherty,
Vice President - Business Development -
I.M. Grossi,
Vice President - Toxicology -
Philip Downing,
Vice President - Preclinical Services -
Andrew Alexander,
Vice President - Pharmacology and Toxicology Operations -
Michael Baim,
Vice President - Bioanalytical Operations -
Beth Taylor,
Chief Financial Officer, Vice President - Finance -
Robert Leasure,
President, Chief Executive Officer, Director -
Gregory Davis,
Interim Chairman of the Board -
Jill Blumhoff,
VP, Finance & CFO -
John P Devine,
VP--Toxicology -
James Sevall Bourdage,
VP, Bioanalytical Services -
Jacqueline M Lemke,
CFO & Vice President--Finance -
Jeffrey Potrzebowski,
VP, Finance & CFO -
John Gregory Beattie,
Chief Operating Officer -
Peterkissinger Candice B Ki...,
-
Daniel Thomas Oakley,
Chief Operating Officer -
Kimberly L Sagartz,
10% owner -
Chrysalis, Llc Sw,
10% owner -
Lori Payne,
VP Bioanalytical Services -
Larry Steven Boulet,
Director -
David W Crabb,
Director -
John B. Landis,
Director -
David L Omachinski,
Director -
Anthony S Chilton,
COO, Scientific Studies -
A. Charlene Sullivan,
Director -
Alberto F Jr Hidalgo,
VP, Bus. Development & Mrkting -
Leslie B Daniels,
Director -
Kathleen Hodges,
Vice President of Quality -
Lina L Reeves Kerner,
V.P. - Human Resources -
Richard M Shepperd,
President & Chief Exec. Off. -
Ronald E Shoup,
Chief Operating Officer -
Craig S Bruntlett,
Sr. V.P. International Sales -
Jon Brewer,
VP Sales/Marketing -
William E Baitinger,
Director -
Candice B Kissinger,
Vice President -
Margaret B Mcclure,
Dir, Pharmaceutical Lab. Div. -
Michael R Cox,
V.P. Finance, CFO -
Emilio Cordova,
V.P. of Business Development -
Edward Chait,
Executive Vice President -
Gerry Henningsen,
Director BAS Evansville -
Donnie A Evans,
Vice President Engineering -
Garyl W Doster,
Director -
Michael P Silvon,
Vice President -
Michael S Noone,
Dir. of Clinical Affairs, Balt -
William Sawyers,
Laboratory Director -
William D Pitchford,
Chief HR Officer